FindTrial
Sign In

Effect and Safety Evaluation of anti-EGFR therapy combined local therapy for unresectable colonrectal cancer Chinese Patients

Effect and Safety Evaluation of anti-EGFR therapy combined local therapy for unresectable colonrectal cancer Chinese Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012626
Enrollment
Unknown
Registered
2017-09-09
Start date
2017-09-18
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colonrectal cancer liver metastasis

Interventions

Intervention Group:chemotherapy and target therapy combined TACE
Control Group:chemotherapy and target therapy

Sponsors

Fudan University Zhongshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with colonrectal cancer liver metastasis, and RAS wild type; 2. No jaundice obstructive; 3. Patients are willing to take cetuximab; 4. Patients are willing to join the research, to accept the informed consent, to privide specimen; 5. Aged above 18 years and lower than 80 years; 6. The lesion can be measured.

Exclusion criteria

Exclusion criteria: 1. Patients who can be followed. 2. Patients who have no ability to determination 3. Patients are taking other targeted therapy. 4. Patients with severe organ funtion disorders. 5. Survival time lower than 3 months 6. Intolerant or allergic to cetuximab 7. Contraindications for cetuximab

Design outcomes

Primary

MeasureTime frame
Image Evaluation;—

Countries

China

Contacts

Public ContactZhou Bo

Fudan University Zhongshan Hospital

zhou.bo@zs-hospital.sh.cn+86 13621604953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026